We are live on !
Find out more
Deerfield Management Portfolio holdings
AUM
$9.6B
Turnover
24.47%
1-Year Est. Return
113.36%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$9.6B
AUM Growth
+$1.11B
(+13%)
Cap. Flow
-$1.32B
Cap. Flow % of AUM
Cap. Flow %
-13.72%
Top 10 Holdings %
Top 10 Hldgs %
53.17%
Holding
94
New
11
Increased
13
Reduced
11
Closed
12
Avg Time Held
1.9
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Genmab
GMAB
|
+$117M |
| 2 |
Mineralys Therapeutics
MLYS
|
+$109M |
| 3 |
Boston Scientific
BSX
|
+$71.4M |
| 4 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$52M |
| 5 |
IDEAYA Biosciences
IDYA
|
+$36.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cogent Biosciences
COGT
|
+$141M |
| 2 |
Catalyst Pharmaceutical
CPRX
|
+$97.6M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$80.4M |
| 4 |
Day One Biopharmaceuticals
DAWN
|
+$79.8M |
| 5 |
Enhabit
EHAB
|
+$66.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.76% |
| 2 | Miscellaneous | 16.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
76
DELISTED
Day One Biopharmaceuticals
DAWN
| – | – |
-3,723,131
| Closed | -$79.8M | – |
|
|
77
DELISTED
Enhabit
EHAB
| – | – |
-4,747,746
| Closed | -$66.9M | – |
|
78
Kymera Therapeutics
KYMR
$9.31B
| – | – |
-561,170
| Closed | -$46.7M | – |
|
79
Myriad Genetics
MYGN
$556M
| – | – |
-505
| Closed | -$2.27K | – |
|
|
80
Neurocrine Biosciences
NBIX
$14.5B
| – | – |
-610,000
| Closed | -$80.4M | – |
|
|
HLSQ
81
Tessera Defense and Homeland Security Inc.
HLSQ
$2.4M
| – | – |
-13,127
| Closed | -$493K | – |
|
|
QSIAW
82
DELISTED
Quantum-Si Inc Warrant
QSIAW
| – | – |
-333,333
| Closed | -$36.2K | – |
|
83
Taysha Gene Therapies
TSHA
$1.31B
| – | – |
-2,722,165
| Closed | -$12.2M | – |
|
84
Veradermics Inc
MANE
$5.79B
| – | – |
-5,000
| Closed | -$316K | – |
|
Similar funds
SC
Deerfield Management's Q2 2026 Portfolio in Review
As of Q2 2026, Deerfield Management held 94 positions worth $9.6B, up 13% from $8.48B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Deerfield Management withdrew a net $1.32B in Q2 2026, closing 12 positions and reducing 11 holdings. Its most notable exit was Catalyst Pharmaceutical, an estimated $97.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Miscellaneous.
Against the trend, Deerfield Management opened a new position in Mineralys Therapeutics worth $107M.
- Deerfield Management's largest Q2 2026 buy was Mineralys Therapeutics: 3,958,000 shares worth $107M.
- Deerfield Management added most to Genmab in Q2 2026, an estimated $117M increase.
- Deerfield Management's biggest Q2 2026 reduction was Cogent Biosciences, cutting an estimated $141M.
- Deerfield Management fully exited Catalyst Pharmaceutical in Q2 2026, selling an estimated $97.6M.
- Deerfield Management's ten largest holdings make up 53% of its $9.6B portfolio in Q2 2026.
- Deerfield Management opened 11 new positions and closed 12 in Q2 2026.
- Deerfield Management's portfolio value rose 13% quarter-over-quarter to $9.6B.
Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.